Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study.

Blood cancer journal·2026
Same author

Upregulation of TCF1 and BCL11B in CD8+ effector T cells predicts favorable response to ibrutinib in patients with chronic lymphocytic leukemia.

Communications biology·2026
Same author

Efficacy and safety of short-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia.

Blood cancer journal·2026
Same author

Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort study.

Blood cancer journal·2026
Same author

A revised staging system for natural killer/T cell lymphoma incorporating skull base invasion and nasal/non-nasal subtype distinction.

Cell reports. Medicine·2026
Same author

TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial.

Med (New York, N.Y.)·2025
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Related Experiment Video

Updated: Jul 18, 2025

Author Spotlight: Flow Cytometric Determination of Pyroptosis in Avian Cells
05:14

Author Spotlight: Flow Cytometric Determination of Pyroptosis in Avian Cells

Published on: May 31, 2024

1.2K

Research Progress on Pyroptosis in Hematological Malignancies.

Tianxin Lyu1, Qingsong Yin2

  • 1Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.

Current Treatment Options in Oncology
|August 27, 2023
PubMed
Summary
This summary is machine-generated.

Pyroptosis, a programmed cell death pathway, is increasingly linked to various diseases. Further research is needed to understand its role in hematological malignancies for potential therapeutic strategies.

Keywords:
Caspase pathwayHematological malignanciesPyroptosis

More Related Videos

Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum
06:12

Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum

Published on: May 3, 2024

2.0K
Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

10.8K

Related Experiment Videos

Last Updated: Jul 18, 2025

Author Spotlight: Flow Cytometric Determination of Pyroptosis in Avian Cells
05:14

Author Spotlight: Flow Cytometric Determination of Pyroptosis in Avian Cells

Published on: May 31, 2024

1.2K
Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum
06:12

Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum

Published on: May 3, 2024

2.0K
Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

10.8K

Area of Science:

  • Cellular Biology
  • Oncology
  • Immunology

Background:

  • Pyroptosis is a distinct form of programmed cell death regulated by caspases.
  • Emerging evidence implicates pyroptosis in diverse pathologies, including cancer and cardiovascular diseases.
  • The precise involvement of pyroptosis in hematological malignancies remains incompletely understood.

Purpose of the Study:

  • To review the fundamental characteristics and regulatory mechanisms of pyroptosis.
  • To explore the specific role of pyroptosis in the pathogenesis of hematological malignant tumors.
  • To discuss potential therapeutic implications of targeting pyroptosis in these cancers.

Main Methods:

  • Literature review of pyroptosis mechanisms and its involvement in diseases.
  • Analysis of current research on pyroptosis in hematological malignancies.
  • Synthesis of findings to identify therapeutic avenues.

Main Results:

  • Pyroptosis exhibits unique features differentiating it from apoptosis and necrosis.
  • Regulatory pathways can either promote or inhibit pyroptosis.
  • Pyroptosis plays a significant role in the development and progression of hematological cancers.

Conclusions:

  • Understanding pyroptosis mechanisms is crucial for deciphering its role in hematological cancers.
  • Targeting pyroptosis pathways may offer novel therapeutic strategies for blood cancers.
  • Further investigation is warranted to fully elucidate pyroptosis's impact on hematological malignancies.